Human placental lactogen (hPL) and human growth hormone (hGH) are members of a multigene family that share amino acid sequence homology and similarity in gene structure and nucleotide sequence, but differ in both function and expression. To determine the sequence requirements for tissue specific expression recombinant plasmids containing the members of the hPL-hGH multigene family and flanking regions were analyzed by both transient and stable transfection assays.
INTRODUCTION
Human placental lactogen (hPL) and human growth hormone (hGH) are polypeptide hormones which are closely related in structure (85% homology in amino acid sequence), but they differ in both function and expression (1) . hGH is involved in the regulation of growth and metabolism during development and hPL stimulates mammary gland development and lactogenesis. hPL is expressed in increasing amounts during pregnancy, accounting for >5% of the total poly(A ;RNA in the placenta during the third trimester of pregnancy (2) , whereas hGH is expressed in the anterior lobe of the pituitary.
The hPL/hGH gene cluster is contained within a 60 kilobase region of DNA on chromosome 17 at region q22-24 (3). There are two hGH genes interspersed with three hPL genes, all in the same transcriptional orientation (4) . A detailed restriction map of this cluster is well defined (4, 5) , and each of the genes have been cloned into plasmid vectors (8) and sequenced (7, 8) . Two of the three hPL genes (hPL, and hPL^) are transcribed in term placenta (6) . Furthermore., the third hPL gene (hPL,), not known to be transcriptionally active in vivo, is capable of directing transcriptional initiation in vitro (9) .
The mechanisms whereby the members of the hPL-hGH multigene family are differentially expressed in a tissue-specific manner are not understood. Tissue specific transcriptional enhancers have been detected in the murine K and heavy chain immuno-globulin genes (10) (11) (12) and may play a role in the tissue-specific differential expression of these genes. Viral enhancers have also been shown to exhibit host cell specificity in their activity (13) . Other striking properties of enhancers include their abilities to function on heterologous promoters regardless of orientation and over long distances (several thousand bp). Although several of these properties have not been demonstrated for all putative enhancers, distal 5' upstream sequences from a number of genes exert a profound effect on the level of transcription and exhibit tissue-specific activity. These control regions, candidates for enhancer-like activity, have been defined for the several eukaryotic genes including: Drosophila glue protein Sgs4 gene (14) , silkworm fibroin gene (15) , mammalian insulin and chymotrypsin genes (16) , and the rat albumin gene (17) .
The elucidation of the mechanisms for the control of gene expression of the members of the hPL-hGH multigene family is complicated by the high se<juenee homology among their structural genes (7, 8) . In the present work, several cell lines transformed by pSV2gpt or pSER recombinants containing the structural genes encoding hPL or hQH have been isolated and shown to express the introduced genes. DNA fragments containing the hPL and hGH structural genes and their flanking regions have been assayed for enhancer function. Transfection assays using plasmid constructs containing a 3.9 kb 3' flanking sequence of the hPLg gene indicates the presence of a transcriptional enhancer within this region. The hPL, gene enhancer functions In an orientation independent manner and in transient transfection assays was able to markedly elevate transcription directed from a heterologous promoter. The enhancer containing sequence has been localized to an AccI-SacI generated 1.0 kb DNA fragment. It is not strictly tissue-specific but shows a marked preference for placental cells.
MATERIALS AND METHODS

Plasmid Constructions
DNA fragments were Isolated from recombinant plasmids that contain the genes for hPL lf hPL 3 , hPL 4 , or hGH (5, 6) . hPLj is contained within a 3.5 kb EcoRI -Xba I fragment, whereas the hPL^, hPL 4 , and hGH genes are carried within 2.9 kb and 2.6 kb EcoRI generated fragments, respectively (5). The hPL^, hPL 4 , and hGH genes were isolated (18) and cloned directly into the unique EcoRI site of pSV2gpt (19) , pSER (12) or pSER2 in the two possible orientations. Cloned inserts are designated (+) or (-) to Indicate their orientation relative to the transcriptional orientation of the gpt gene. The hGH gene cloned in all the constructs (Fig. 1 ) refers exclusively to hGHj and not the variant gene, hGH 2 (4, 5) . The EcoRI-Xbal fragment that contains the hPLj gene was cloned into the same site following EcoRI linker addition (20) . hGH-hPL flanking regions were cloned in the same site after EcoRI digestion of recombinant phage XH19, XH20, and XH22 previously selected from a human genomic DNA library (5) . Another cloning vector, pSER2, was constructed from pSV2gpt by PvuII -Spjil double digestion followed by a T 4 -DNA polymerase-catalyzed fill-in and blunt-end llgation of filled-in hPLj using T 4 Cloned intergenic and flanking regions are indicated by nurbered fragments (e.g. fragl through 9). The EcoRI fragments, designated (+) or (-) depending on their orientation relative to the gpt gene, were cloned into the EcoRI site of pSER. Fragment 1 has an artificial EcoRI site produced upon cloning into X Charon 4A.
0.1% SDS with 4 changes of 10 min each followed by 4 washes at 42°C in 0.1 x SSC, 0.1% SDS at 30 min each. The filter was exposed to X-ray films for 1-3 days in the presence of intensifying screens.
RESULTS
Subcloning of hPL and hGH Structural Genes in pSV2gpt and pSER; Transfection of JEG-3 Cells
EcoRI fragments encoding the entire hPL^, hPL 4 , and hGH structural genes were cloned Into the EcoRI site of the vector pSV2gpt or pSER in both possible orientations designated (+) or (-) relative to the direction of transcription of the gjrt gene (Fig. 1) . The EcoRI -Xbal fragment that contains the hPLj gene was cloned into the EcoRI site of pSV2gpt following EcoRI linker addition. Another pSER cloning vector was constructed, designated pSER2, which has an EcoRI site in place of the deleted PvuII -SphI fragment containing the SV40 enhancer region. hPL 3 and hGH structural genes were cloned in place of the deleted SV40 enhancer such that in one of the orientations (designated (-)) the 5' region is adjacent to the gjrt promoter. The DNA constructs illustrated in Fig. 1 were successfully introduced into JEG-3 cells, and stably transformed cell lines were obtained. These cell lines were derived from pools of 50-100 or 4-8 individual transfectants in the case of pSV2gpt and pSER, respectively.
Detection of Enhancer Activity Within a Flanking Region
To screen the Intergenic regions of the hPL-hGH multigene cluster for enhancer activity, EcoRI fragments flanking the hGH and hPL 3 genes were cloned into the EcoRI The transformation frequencies were normalized to the frequency obtained with pSV2gpt (1.1x10 for JEG-3 cells). All transfections were done in duplicate and in the case of pSV2gpt, pSHt, pSERfragl(+), pSERfragl(-), pSER2fragl(+) and pSER2fragl(-), the frequencies listed were deduced from at least three different experiments using two different plasmid preparations. site of pSER (Fig. 2) . When pSER was used to transfect JEO-3 cells, the transformation frequency (relative to that of the plasmid pSV2gpt) was reduced by a factor of more than 30 (Table D. The DNA fragments shown in Figs. 1 and 2 were tested for their ability to substitute for the SV40 enhancer. These fragments include the structural genes for hQH, hPLg and hPL 4 as well as selected flanking regions (Fig. 2) . As shown in Table I , the hPL and hQH structural genes did not contain DNA sequences capable of substituting for the deleted SV40 enhancer region. However, the structural gene sequences were at least 2 kb from the gpt promoter. Consequently, hPL 3 and hQH structural genes cloned into an EcoRI site close to the gpt promoter of pSER2 were also tested (Table I, considered that the 5' end of the hGH and hPL genes were the best candidates for enhancer activity. However, even in the orientation (designated (-)) when the 5' end was nearest the g£t promoter this sequence failed to exhibit enhancer activity (Table I) . Large EcoRI digested flanking regions cloned Into pSER were also tested ( Fig. 2 and Table I ). The pSERfragl(+) clone containing a 3.9 kb 3' flanking region of the hPL 3 gene exhibited an almost 10-fold higher transformation frequency compared to the pSER vector (Table I) (Table I) .
The Enhancer can Directly Activate Transcription of a Heterologous Promoter
Relative transformation frequency assays have proved to be a valid test of enhancer activity (12,34,35) . A more direct assay of the effect of enhancers on transcription using the E.coli CAT gene was developed by Gorman et al. (21) . Using this transient assay (Fig. 3) Fig. 2) cloned in an EcoRI site 3' to the CAT gene.
The elevated CAT activity observed with pSV!CATfragl(+) transfection was observed in five independent experiments using two different plasmid preparations. pOTOD contains a thymidine klnase promoter in a CAT vector. presence of enhancer sequences (TableD-Other than the hPLg enhancer (fragmentl), no other enhancer containing sequences were found using this assay. Since the stable transformation assays were performed using JEG-3 cells as recipients it was possible that any enhancers present were acting in a cell-type specific manner. Consequently, we examined the hGHj section of the cluster for a hGH enhancer elements, using 18-54,SF cells as recipients in CAT assays. Fragments 4 and 5 as well as the hGH} structural gene were cloned into the Bam HI site of pSVlCAT. Each construct was introduced into both JEG-3 and 18-54,SF cells and CAT assays were performed. No construct exhibited higher activity than that observed with pSVlCAT (data not shown) and we conclude that there is no enhancer associated with the hGH 1 region of the cluster that is detectable under the conditions used.
In several of the constructs assayed in Table I , the structural hPL or hGH genes contained promoter regions spanning 500 bp upstream from the transcriptional start. It The ability of the cloned fragments to substitute for the deleted SV40 enhancer was assessed by CKT assay. was considered that the presence of two promoters in the pSER construct (SV40 and hPL or hQH) may interfere with the enhancer assay. The 500 bp EcoRI-BamHI fragments that contain the hQH and hPL promoters (9) were cloned upstream of the promoter-less pCAT3M vector (pC3GEB and pC3hPL 3 EB, respectively). These two constructs were introduced into both JEO-3 and 18-54,SF cells and CAT assays were performed. Neither of these constructs exhibited CAT activity above that observed for pSVlCAT (data not shown). It is concluded that the 500 bp EcoRI-BamHI promoter containing segment does not contain an enhancer and furthermore the promoters did not exhibit cell-type preference as assessed by CAT activity (data not shown). Localization of the Enhancer within the hPL^ Flanking Region Fragment 1 was cloned into the EcoRI site of pSVlCAT and CAT assays demonstrated that fragment 1 contains an enhancer that can act directly to increase transcriptional activity from a heterologous promoter (Figs. 3 and 4) . The enhancer containing fragment 1 was purified and digested with a series of endonucleases and a number of subfragmenta were cloned into pSVICAT (Fig. 4) . CAT assays demonstrated that Sau3A fragments, designated Sj through Sjy, did not contain sequences capable of acting as an enhancer (data not shown). The same assay system demonstrated that the enhancer is located within an AccI-SacI generated fragment of approximately 1.0 kb (Fig. 3, 4; pSVlCATAS) . Presumably, the Sj, SJJ and SJJJ fragments contain only part of the active enhancer sequence and this is why they failed to exhibit enhancer activity (data not shown).
The hPL 3 Enhancer is not Strictly Cell-Type Specific
The hPL 3 enhancer is not strictly tissue specific since it functions in human-cell lines of placenta! (JEG-3) and pituitary (18-54.SF) origin (Fig. 3 and 5) . Nonetheless, the enhancer in pSVlCATAS functions more efficiently, relative to the SV40 enhancer activity, in JEG-3 cells than in 18-54.SF cells. Enhancer efficiency was estimated from densitometric scans of the products of the CAT assay. In placental cells the hPL enhancer fragment 1 has twice the activity of the SV40 enhancer while the subcloned fragment IAS has -9 times the activity of the SV40 enhancer. In pituitary cells fragment 1 has about the same enhancer activity as SV40, while the subfragment AS has about onehalf the activity of the SV40 enhancer. These experiments show that the hPL^ enhancer is severalfold more active than the SV40 enhancer in placental cells but much less active in pituitary cells. Since the EA fragment (Fig. 4) is a subfragment of Sj, its failure to exhibit enhancer activity (Fig. 3 and 5) is expected.
DBCU3SION
In the present work, a highly efficient enhancer of the hPL 3 gene has been identified. The hPL 3 enhancer has all three of the major distinguishing characteristics of a transcriptional enhancer: function is independent of orientation and position relative to the transcriptional start and it can act on a heterologous promoter to directly stimulate transcriptional activity (Table I ; Fig. 3 and 5) . The hPL 3 enhancer has been localized to a 1 kb region -2 kb downstream from the hPLg gene. The enhancer fragment enhances CAT expression in human placental cells (JEG-3) -9 times more than the SV40 enhancer but only one-half as efficiently as the SV40 enhancer In pituitary cells (Fig. 3 and 5) . Thus, this highly efficient enhancer shows -20 fold tissue preference for placental cells relative to pituitary cells, but not strict tissue specificity. The ability of this sequence to dramatically stimulate transcription clarifies the prominant role the hPL 3 gene plays in placental lactogen synthesis (-lg/day in term placenta).
The location of the enhancer adjacent to the hPL 3 gene makes a compelling argument that its biological role is to enhance hPL 3 gene transcription. Barsh et al (4) screened the hPL/hGH multigene family for sequences related to hPL. They found only the five hPL and hGH genes with no homology within 16 kb 3 1 of the hPL 3 gene. Thus, there is no evidence for a transcribed gene within 6 kb of the enhancer except for the hPL 3 gene. It is not surprising that hPLg has a strong enhancer. Five to ten percent of the total mRNA in term placenta is hPL mRNA (6) and all of it is transcribed from two genes, hPL 3 and hPL 4 . About 10-20% of it is transcribed from hPL 4 and 80-90% from hPL 3 (6) . In vitro transcription experiments in a Hela cell extract showed similar promoter efficiencies for the two genes. Perhaps Nature was clever to insert an enhancer 3 1 of the outside gene (hPL 3 ) of the cluster rather than 5' of the gene, because of the possibility of its influencing hGH transcription (hGH 2 and hPLj are separated by 6 kb). The control of hPL expression is poorly understood. In contrast, the other members of the multigene family, hGH and prolactin, have been extensively studied. Two groups (36, 37) have used experiments with different gene-fusion constructs to suggest that transcription of the hGH gene is stimulated in the presence of dexamethasone. However, there is disagreement on the regions responsible for this induction, with some authors (31) implicating the first intron sequence and others (37) the region within 500 bp 5' to the hGH transcriptional start site. Experiments described in the present work failed to detect an enhancer within the hGH or hPL 4 structural genes or their 5' and 3' flanking regions. These experiments were performed in the absence of added hormones and consequently, enhancer sequences that are hormone inducible would not be readily detected. Hence, the hPL 3 enhancer described here remains the only enhancer so far detected in the hGH/hPL multigene cluster. It would seem that In the evolution of this multigene family the regulation of the hPL genes has been radically altered from that of the hGH genes. This is interesting when it is considered that the hGH and hPL genes are thought to have evolved from a duplicated ancestoral gene (1) and recently (-10 million years ago) underwent a gene conversion event leading to the high homology found in the multigene complex (4, 38) . During evolution of this multigene family an enhancer from elsewhere in the genome may have been translocated to its present position in the 3' flanking region of the cluster. Such an event would explain the high expression of hPLî n vivo, and would explain why the other hPL and hGH genes or its flanking regions do not possess a counterpart to the hPLj enhancer. In several cell lines, translocations or retroviral insertions have been shown to lead to transcriptional activation of adjacent genes. This mechanism of gene activation has been reported to play a role in c-myc expression in Manca cells (39) , interleuldn-3 expression in WEHI-3B cells due to retroviral insertion 5' upstream of the gene (40) , and interleukin-2 production in MLA144 cells due to retroviral insertion 3' to the gene (41) .
There is considerable evidence that enhancers are regions of DNA where sitespecific DNA binding proteins interact (42) . Specific interactions have been described between nuclear proteins and the polyoma virus (43) and immunoglobulin heavy chain (44) enhancers. The search for trans-acting factors that interact specifically with the hPL,3 enhancer in placental tissues is in progress.
